OCUGEN, INC. Derivative Liability, Current
OCUGEN, INC. (OCGN) had Derivative Liability, Current of $33.71 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DerivativeLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Derivative Liability, Current $33.71M.
- 2025-12-31: Derivative Liability, Current $0.00.
- 2019-06-30: Derivative Liability, Current $42.07K.
- 2018-12-31: Derivative Liability, Current $1.74M.
| Period end | Derivative Liability, Current |
|---|---|
| 2026-06-30 | $33.71M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-06 |
| 2019-06-30 | $42.07K 8-K/A · filed 2019-10-07 |
| 2018-12-31 | $1.74M 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |